1.37

2.14% -0.03

After Hours: 1.35 -0.02 -1.46%

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is traded at $1.37, with a volume of 39,856. It is down -2.14% in the last 24 hours and down -8.67% over the past month. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Previous Close:

$1.40

Open:

$1.36

24h Volume:

39,856

Relative Volume:

0.54

Market Cap:

$7.98M

Revenue:

Net Income/Loss:

$-14.29M

P/E Ratio:

-0.3434

EPS:

-3.99

Net Cash Flow:

$-12.27M

1W Performance:

-3.52%

1M Performance:

-8.67%

6M Performance:

-25.94%

1Y Performance:

-65.51%

1-Day Range:

$1.36

$1.40

1-Week Range:

$1.36

$1.49

52-Week Range:

$1.31

$5.00

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1135)

Industry

Biotechnology (635)

Phone

215-948-4119

Address

3805 OLD EASTON ROAD, DOYLESTOWN, MA

Employee

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

APRE's Discussions on Twitter

Compare APRE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APRE Aprea Therapeutics Inc	1.37	8.16M	0	-14.29M	-12.27M	-3.99
VRTX Vertex Pharmaceuticals Inc	421.67	109.22B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	628.00	67.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	423.47	57.35B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	831.48	50.87B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	182.77	39.72B	447.02M	-1.18B	-906.14M	-6.1812

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

12:48 PM

Tools to assess Aprea Therapeutics Inc.’s risk profileWeekly Stock Report & High Return Trade Guides - newser.com

12:48 PM

06:20 AM

Is Aprea Therapeutics Inc. stock attractive for growth ETFsJuly 2025 Action & Fast Entry and Exit Trade Plans - newser.com

06:20 AM

04:30 AM

Will Aprea Therapeutics Inc. stock outperform value stocksJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com

04:30 AM

04:26 AM

Is Aprea Therapeutics Inc. stock attractive after correction2025 Sector Review & Growth Oriented Trade Recommendations - newser.com

04:26 AM

Nov 03, 2025

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge - openPR.com

Nov 03, 2025

Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside - FinancialContent

Nov 03, 2025

Aprea Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Nov 03, 2025

Is Aprea Therapeutics Inc. stock poised for growthPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com

Nov 03, 2025

Why Aprea Therapeutics Inc. stock could outperform in 2025Trade Exit Summary & Low Risk High Win Rate Picks - newser.com

Nov 03, 2025

Nov 02, 2025

Risk vs reward if holding onto Aprea Therapeutics Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com

Nov 02, 2025

Oct 31, 2025

Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo

Oct 31, 2025

Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN

Oct 31, 2025

Oct 30, 2025